Auryxia generic
Auryxia is an anti-diabetic drug owned by Keryx Biopharms. The active ingredient of Auryxia is ferric citrate. The drug was first authorized for market use on 5th September, 2014. Auryxia holds 15 patents, with one still pending as of writing.
When will Auryxia generic be available?
The potential for a generic version of Auryxia to be released exists, with the earliest possible release date being 21st July, 2030. The last patent of Auryxia is due to expire on this date.
Auryxia uses
Auryxia is available in tablet form and is administered orally. The drug is used to manage serum phosphorous levels, which can be highly beneficial for patients needing control over these levels. The effectiveness of Auryxia is largely due to its active ingredient, ferric citrate.
Auryxia patent expiration
Auryxia, owned by Keryx Biopharms, holds 15 patents, with one already expired. The last patent is set to expire on 21st July, 2030. Consequently, an Auryxia generic could potentially be released after this date. Below are the details of the patents: